We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
Cap. Flow
-$34.2M
Cap. Flow %
-1.55%
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
TRAX
First Tracks Biotherapeutics
TRAX
+$38M
2
ROIV icon
Roivant Sciences
ROIV
+$28.1M
3
AVTX icon
Avalo Therapeutics
AVTX
+$24.6M
4
RVMD icon
Revolution Medicines
RVMD
+$21.9M
5
INSM icon
Insmed
INSM
+$20.6M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$55.6M
2
ACLX
Arcellx
ACLX
+$41.7M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.2M
4
TERN
Terns Pharmaceuticals
TERN
+$29.7M
5
APGE icon
Apogee Therapeutics
APGE
+$26.8M

Sector Composition

Rank Sector Weight
1 Healthcare 89.73%
2 Miscellaneous 9.21%
3 Financials 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OKUR
101
OnKure Therapeutics
OKUR
$145M
$1.1M 0.05%
240,963
– –
ENGN icon
102
enGene Therapeutics
ENGN
$122M
$1.04M 0.05%
600,000
-10,370
-2% -$42.3K
XFOR icon
103
X4 Pharmaceuticals
XFOR
$402M
$677K 0.03%
145,000
– –
BOLD
104
Boundless Bio
BOLD
$65.1M
$625K 0.03%
+250,000
New +$385K
LENZ
105
LENZ Therapeutics
LENZ
$183M
$568K 0.03%
100,000
– –
QTTB icon
106
Q32 Bio
QTTB
$359M
$354K 0.02%
27,777
– –
OBIO icon
107
Orchestra BioMed
OBIO
$299M
$144K 0.01%
33,400
-369,150
-92% -$1.51M
NXTC icon
108
NextCure
NXTC
$36.4M
$67.1K ﹤0.01%
41,960
-199,866
-83% -$1.48M
ADGM
109
Adagio Medical Holdings
ADGM
$12.4M
$52.1K ﹤0.01%
80,000
– –
RCKTW icon
110
Rocket Pharmaceuticals Warrant
RCKTW
$278 ﹤0.01%
75,000
– –
ACLX
111
DELISTED
Arcellx
ACLX
– –
-362,764
Closed -$41.7M
BBIO icon
112
BridgeBio Pharma
BBIO
$14.5B
– –
-150,000
Closed -$11.1M
BMY icon
113
CALL
Bristol-Myers Squibb
BMY
$136B
– –
-300,000
Closed -$18.2M
CELC icon
114
CALL
Celcuity
CELC
$4.67B
– –
-30,000
Closed -$3.42M
CGON icon
115
CALL
CG Oncology
CGON
$6.6B
– –
-60,000
Closed -$4.06M
CNTA
116
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,400,000
Closed -$55.6M
CORT icon
117
Corcept Therapeutics
CORT
$12B
– –
-50,000
Closed -$2.02M
DNTH icon
118
CALL
Dianthus Therapeutics
DNTH
$6.04B
– –
-50,000
Closed -$4.2M
IBRX icon
119
PUT
ImmunityBio
IBRX
$8.55B
– –
-1,250,000
Closed -$9.59M
KZR
120
DELISTED
Kezar Life Sciences
KZR
– –
-229,076
Closed -$1.7M
NVO
121
CALL
Novo Nordisk
NVO
$206B
– –
-175,000
Closed -$6.43M
RVMD icon
122
PUT
Revolution Medicines
RVMD
$44.8B
– –
-100,000
Closed -$9.72M
SPY icon
123
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$814B
– –
-200,000
Closed -$130M
TERN
124
DELISTED
Terns Pharmaceuticals
TERN
– –
-562,631
Closed -$29.7M
WVE icon
125
Wave Life Sciences
WVE
$960M
– –
-1,401,727
Closed -$10.2M
1 2 3 4
5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
  • Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceuticals, cutting an estimated $34.2M.
  • Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
  • Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
  • Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
  • Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.